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treatment of peri-implant diseases. Materials and Methods: An electronic systematic search was
conducted by using the following databases: PubMed (Medline), Elsevier EMBASE, Web of Science, and
Cochrane Central Register of Controlled Trials (CENTRAL), EBSCO-Dentistry and Oral Science Source, and
WHO International Clinical Trials Registry Platform (WHOINT) from January 1980 to March 2020
(Registration in PROSPERO:CRD42018114147). Randomized controlled clinical trials with at least 10
patients with peri-implant diseases, treated with or without adjunct local or systemic antibiotics along
with surgical or non-surgical therapies, and minimal three months follow up were included. Meta-analyses
were performed to analyze weighted mean differences (WMD) in pocket depth (PD) reduction,
radiographic bone level (RBL) gain, and odds ratio (OR) of treatment success. Subgroup analyses were
conducted based on different diseases or type of antibiotics. Results: From 856 articles identified, 10
articles met the inclusion criteria were selected. Among them, 6 articles were included for meta-analysis.
Adjunct antibiotics in the treatment of peri-implant diseases showed significant more PD reduction ( 3
mo: WMD = 0.56 mm, p = 0.001; 6 mo: WMD = 0.77 mm, p < 0.00001; 12 mo: WMD = 0.92 mm, p <
0.00001), RBL gain (WMD = 0.64 mm, p = 0.03) and treatment success ( OR = 1.74, p = 0.04) compared to
the same treatment without adjunct antibiotics. Subgroup analysis showed the clinical benefit of
antibiotics is especially significant in the treatment of peri-implantitis, not as much in peri-implant
mucositis. Conclusion: From the current evidence, adjunct antibiotics provided additional beneficial effect
up to 12 months in the treatment of peri-implant diseases, including PD reduction, RBL gain and treatment
success.
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Abstract
Aim: The aim of this systematic review was to assess the clinical effect of adjunct antibiotics in
the treatment of peri-implant diseases. Materials and Methods: An electronic systematic search
was conducted by using the following databases: PubMed (Medline), Elsevier EMBASE, Web of
Science, and Cochrane Central Register of Controlled Trials (CENTRAL), EBSCO-Dentistry and
Oral Science Source, and WHO International Clinical Trials Registry Platform (WHOINT) from
January 1980 to March 2020 (Registration in PROSPERO:CRD42018114147). Randomized
controlled clinical trials with at least 10 patients with peri-implant diseases, treated with or without
adjunct local or systemic antibiotics along with surgical or non-surgical therapies, and minimal
three months follow up were included. Meta-analyses were performed to analyze weighted mean
differences (WMD) in pocket depth (PD) reduction, radiographic bone level (RBL) gain, and odds
ratio (OR) of treatment success. Subgroup analyses were conducted based on different diseases or
type of antibiotics. Results: From 856 articles identified, 10 articles met the inclusion criteria were
selected. Among them, 6 articles were included for meta-analysis. Adjunct antibiotics in the
treatment of peri-implant diseases showed significant more PD reduction ( 3 mo: WMD = 0.56
mm, p = 0.001; 6 mo: WMD = 0.77 mm, p < 0.00001; 12 mo: WMD = 0.92 mm, p < 0.00001),
RBL gain (WMD = 0.64 mm, p = 0.03) and treatment success ( OR = 1.74, p = 0.04) compared to
the same treatment without adjunct antibiotics. Subgroup analysis showed the clinical benefit of
antibiotics is especially significant in the treatment of peri-implantitis, not as much in peri-implant
mucositis. Conclusion: From the current evidence, adjunct antibiotics provided additional
beneficial effect up to 12 months in the treatment of peri-implant diseases, including PD reduction,
RBL gain and treatment success.
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Review of Pertinent Literature
History of Modern Implant Dentistry and Concept of Osseointegration
The era of modern implant dentistry was stemmed in 1952, when the Swedish orthopedic
surgeon Per-Ingvar Brånemark inadvertently discovered osseointegration between an implant and
the rabbit bone using vital microscopy. Recognizing the value of osseointegration, Dr. Branemark
and his colleagues, as well as other Europeans (including Switzerland’s Andre Schroeder at the
University of Berne), started to research the clinical application of osseointegration in dentistry.1
By 1978, the National Institutes of Health-Harvard University consensus conference was held to
examine the model development, benefits, and risks of dental implants, as well as a successful
dental implantation procedure for clinicians to follow.2 This conference marked the transition out
of an era in which implants were considered as an unreliable and just an experimental method for
tooth replacement.
To fulfill the procedural guide for dental implantation, Albrektsson et al conducted a
human study in 1981 and gave one of the first definitions of dental implant osseointegration. They
examined thirty-eight long-term functioning threaded, cylindrical titanium implants from
jawbones, tibial bones, or iliac bones for histological ultrastructural analysis. Using the X-rays,
stereomicroscope and transmission electron microscope, they were able to take a closer look at the
bone-implant interface. They found that no wear products were seen in the bone or soft tissues in
spite of 90 months of loading times. The bone covering the implants appeared as dense lamellae,
and the collagen fibers were tightly adhered to titanium surface; while the soft tissues on the upper
part of jawbone implants were closely adhere to titanium surface to form a biological seal. The
cells on that soft tissue-implant inter-surface were polygonal epithelial cells, but no white blood
cells nor any types of inflammatory cells infiltrating the border area. The author then described
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osseointegration as a “direct functional and structural connection between living bone and the
surface of a load-bearing implant”.3 Subsequently, Branemark also illustrated the concept of
osseointegration in a more detailed manner. He described that the interface between tissue and the
integrated titanium tooth root implants was “a shell of compact cortical bone formed around the
implant without any apparent soft tissue intervention between normal bone and the surface of the
implant”.4 Therefore, osseointegration unites bone to an implant surface, with a direct structural
and functional connection without intermediate fibrous tissue or fibrocartilage formation.5
Besides the histological point of view, clinical studies since 1978 at the Harvard
Conference have proven the predictability of biological healing of dental implants and mechanical
function of implant prosthesis. In 1981, a longitudinal study of 2768 implants (371 consecutive
patients) with fixed implant prostheses on edentulous jawbones was conducted by Adell et al,
which showed that 81% of maxillary implants and 91% of mandibular implants remained stable
after an observation time of 5-9 years. The article also revealed that the mean bone loss was 1.5mm
on the upper jaw and 0.7mm on the lower jaw during the healing period (from fixture installation
to abutment connection). After abutment connection, only 0.1mm of marginal bone was lost
annually during the remodeling period.6

Implant Success and Failure
Many experimental and clinical studies have been conducted after then, to focus on the
mechanism of tissue integration in different types and designs of the implants, reasons of implant
failure, and how to secure long-term success. In the beginning, the definitions on implant success
or failure were very arbitrary and based on anecdotal clinical observations. Implant was considered
successful when it meets its defined success criteria in terms of function (ability to chew), tissue
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physiology (presence of osteointegration, absence of pain and other pathological processes), and
user satisfaction (esthetics and absence of discomfort). In 1986, Albrektsson proposed a minimum
criteria for the dental implant success, which included (1) an individual, unattached implant is
immobile, (2) radiographically no evidence of peri-implant radiolucency, (3) vertical bone loss
less than 0.2mm annually following the implant’s first year of service, (4) absence of persistent
and/ or irreversible signs and symptoms such as pain, infections, neuropathies, paresthesia, or
violation of the mandibular canal, (5) in the context of the above, they reported a successful rate
of 85% at the end of a five-year observation period and 80% at the ten-year period.7 This criteria
was widely used for defining implant success in clinical studies and practice, however, it did not
address the process of tissue changes around implants, which led to the loss of implants.
While implant failure is the term used for implants that require removal or have already
been lost, failing implant is the term to be used where any symptoms or signs are distinguished as
early changes preceding the loss of osseointegration.8 In 2008, a group of clinicians in the
International Congress of Oral Implantologists (ICOI) published a consensus article in the journal
Implant Dentistry with the updated definition on implant success, implant survival, and implant
failure.9 From their definition of implant success, it is suggested to include a time period of at
least one year for implants serving as prosthetic abutments. And there are three life spans
determining the early, intermediate, and long-term success of implants: Early success spans 1 to 3
years, intermediate success spans 3 to 7 years, and long-term success spans more than 7 years.
They also provided the scales and criteria of implant quality of health for the clinicians to evaluate
and then to treat the condition accordingly (see Table 1).

Table 1. ICOI Implant Quality Scale
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Implant Quality Scale
Success

Satisfactory survival

Compromised survival

Failure

Clinical conditions
No pain or tenderness upon function
No mobility
<2mm radiographic bone loss from initial surgery
No exudates history
No pain on function
No mobility
2-4mm radiographic bone loss from initial surgery
No exudates history
May have sensitivity on function
No mobility
>4mm radiographic bone loss from initial surgery
(less than ½ of implant body)
• Probing depth >7mm
• May have exudates history
Any of the following
• Pain on function
• Mobility
• Radiographic bone loss > ½ length of implant
• Uncontrolled exudate
• No longer in mouth
•
•
•
•
•
•
•
•
•
•
•

Failing Implant
To prevent implant failure, the upmost is to understand the factors related to implant loss
and the process of implant failing. Implant failures can be resulted from (1) biological
complications, (2) mechanical or technical complications, (3) inadequate patient adaptation.8, 10
Mechanical or technical complications serve as a collective term for mechanical damage of the
implant, implant components, or supra-structures. They should and could be avoided by adequate
design of implants by the manufacturers, as well as adequate treatment planning and treatment
administration by the clinicians. Inadequate patient adaptation is related to psychological,
esthetical, and phonetical problems. Biological complications refer to disturbances in the function
of implants characterized by biological processes that affect the tissues supporting the implants.11
Biological complications can further be subdivided into early and late complications: Early
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complications happen before the implant loading, while late complications happen after implant
loading.12
Radiographic evidence of bone loss around the implants provides essential information for
the assessment of implant outcome. So far, no reference in the literature can indicate the amount
or rate of bone loss which ultimate leads to implant failures. Peri-implant bone loss may be resulted
from normal remodeling to overloading, microgap leakage, or inflammation/ infection.13
Albrektsson and Isidor defined an inflammatory process which affect the soft and hard tissues
surrounding osseointegrated dental implants as peri-implant diseases.14 Peri-implant disease
include peri-implant mucositis and peri-implantitis. Peri-implant mucositis is reversible
inflammatory reaction confined to soft tissues around the implants, while peri-implantitis refers to
inflammatory condition extends to the supporting bone.15 Previous studies have shown the
prevalence rate of peri-implant mucositis is approximately 80% of the subjects and in 50% of the
implants,16 while peri-implantitis was found in between 28% and 56% of subjects and 12 to 43%
of implants over 5 years of follow-up.15, 17

Etiology and Pathophysiology of Peri-Implant Diseases
According to the definition, any sign of bone loss from inflammation may be interpreted
as indicative of peri-implantitis. Evidence has shown that poor oral hygiene, smoking, history of
periodontitis, diabetes, genetic traits, alcohol consumption and some implant surface are potential
risk indicators for peri-implant disease.18 As a local factor, a well-functioning marginal mucoperiosteal-osseous barrier zone is a key to maintain a healthy state around a dental implant. To
elucidate the marginal tissue reactions after implant insertion, several studies have been conducted
based on animal models or human trials.
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In 1986, a cross-sectional study was conducted by Lekholm. He had participants selected
randomly from a pool of 400 subjects. All the patients had implants and fixed dentures for at least
6 months to 15 years. Samples of subgingival microbiotia were harvested by curettes from the sites
showing the deepest and shallowest pockets in each jaw of patient. In this study, only 45% of the
abutments were free of plaque, and 80% of abutments were surrounded by inflammatory gingiva.
The presence of plaque and gingivitis was significantly correlated. And significant correlations
were established between presence of gingivitis or deeper pockets and occurrence of filiforms and
small spirochetes.19 This study illustrated that microbial plaque could be associated with the
ecosystem around dental implants and plays a role in inflammation of gingiva around the implants.
Then in 1987, Mombelli conducted a study to compare the composition of the microbiota
around “successful” and “failing” implants. The author selected patients from a recall group of
implant wearers who had 2 or 4 hollow cylinder titanium implants on the mandible for more than
1 year. Based on a threshold of 5mm probing depth, the patients were divided into either successful
group (Group S) or failing group (Group U). The clinical parameters retrieved were plaque index,
sulcus bleeding index, and gingival index. For darkfield microscopic examination of microbiota,
subgingival samples were obtained from 2 sites of contralateral implants in Group S, while the
healthiest and most diseased site were chosen in Group U. Their results showed that in group S,
the predominant morphotype of bacteria were coccoid, and no spirochetes were found. However,
significantly elevated count of anerobic bacteria was found in the diseased site of group U. Gramnegative anaerobic rods accounted for more than 50% of cell count in more than one half of the
samples. Black pigmented Bacteroides, especially Bacteroides intermedius, were found regularly
and accounted for up to 30% of the total cultivated microbiota. Fusobacterium spp. were also
commonly found around failing implants, comprising mean proportions of 15.3% of anaerobic
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count. They concluded that the composition of subgingival plaque samples varied considerably
when taken from healthy or diseased implant sites within the same patients, and peri-implantitis
should be regarded as a site-specific infection.20
In 1992, Berglundh and Lindhe et al performed an experiment on animal models to
examine the soft tissue reaction to de novo plaque formation on implants and to compare with the
reaction around teeth. They found a similar barrier function tissue reaction on the gingiva around
implants to teeth. They both had increase of the leukocyte transmigration in the junctional
epithelium, and the volume occupied by inflammatory cells in the two connective tissue lesions
was also similar.21 In 1994, Pontoriero et al conducted an experimental human study to compare
the clinical and microbiological parameters during the development of gingivitis and peri-implant
mucositis 6 months following implant installation. The results showed that after 3-week period of
no oral hygiene care, the clinical index values increased significantly at both implant and tooth
sites. Plaque accumulation was at similar rates and the mean values of clinical parameters were
also very similar at implant site and tooth site at any observation periods.22
In 2000, Van Winkelhoff et al studied the early colonization of peri-implant pockets by
putative periodontal pathogens in 20 partially edentulous patients. The authors found the most
commonly seen periodontal pathogens, P. gingivalis, F. nucleatum, P. intermedia, and T. forsythia,
were identified as early as 6 months after loading. In particular, P. gingivalis was significantly
associated with the presence of fistula and implant loss.23
Lastly, a recent review article which collected 29 reports on subjects with peri-implant
diseases revealed that in most cases the composition of the flora is similar to the subgingival flora
of chronic periodontitis and is dominated by Gram-negative bacteria. They concluded peri-implant
diseases can be viewed as a mixed anaerobic infection.24 From all these evidence, it is well
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demonstrated that the combination of multiple pathogenic bacteria in the subgingival plaque plays
an important role in the initiation and progression of peri-implant diseases. And the reduction of
the bacterial load to a level compatible with health is an important aspect in the treatment of periimplant diseases.25

Diagnosis of Peri-implant Diseases
The consensus report on the definition, diagnosis, and treatment of peri-implant diseases
was once published in 2008 at the 6th European workshop on periodontology. By that time the
clinical diagnosis of peri-implant disease was still very vague. For example, they stated that
probing is essential for diagnosis of peri-implant diseases, and bleeding on probing indicates the
presence of inflammation in the peri-implant mucosa. They also mentioned an increase in probing
depth over time is associated with the loss of attachment and supporting bone.17 No definitive cut
off value for probing depth or bone loss was provided. Later, the American Academy of
Periodontology also published a statement on peri-implant mucositis and peri-implantitis in regard
to the diagnosis and clinical implications in 2013. In this report, they suggested that the signs to
determine peri-implant mucositis include bleeding on probing and/ or suppuration, with associated
probing depths ≥ 4mm and no evidence of radiographic bone loss beyond bone remodeling.
However, when these parameters are present with any degree of detectable bone loss following the
initial bone remodeling after implant placement, a diagnosis of peri-implantitis is made. If no
baseline radiograph is available, then a threshold vertical distance of 2mm from the expected
marginal bone level following remodeling should be used for diagnosing peri-implantitis.26
The most recent classification for peri-implant diseases and conditions was presented by
the Workgroup 4 of the 2017 world workshop. Five position articles described the characteristics
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of peri-implant mucositis, peri-implantitis, and soft/ hard tissue deficiencies. To diagnose periimplant mucositis, it requires (1) presence of bleeding and/ or suppuration on probing with or
without increased probing depth compared to previous examinations, and (2) absence of bone loss
beyond crestal bone level changes resulting from initial bone remodeling. To diagnose periimplantitis, it requires (1) presence of bleeding and/ or suppuration on probing, (2) increased
probing depth compared to previous examinations, and (3) presence of bone loss beyond crestal
bone level changes resulting from initial bone remodeling. If in the absence of previous
examination data, then the diagnosis of peri-implantitis can be based on the combination of (1)
presence of bleeding and/ or suppuration on gentle probing, (2) probing depths of ≥ 6mm, and (3)
bone levels ≥ 3mm apical of the most coronal portion of the intraosseous part of the implant.27

Management of Peri-implant Disease
Based on the notion that the development of subgingival microflora is associated with periimplant diseases, decrease bacterial load from the implant surface becomes the main objective in
the treatment of peri-implant mucositis and peri-implantitis.28
Peri-implant mucositis is believed to be the precursor of peri-implantitis, in the same way
that gingivitis is the precursor of periodontitis. Mechanical therapy with or without adjunctive use
of antiseptic rinses is usually the initial treatment of choice. Patient’s plaque control is also an
important factor for treatment success.28
In regard to peri-implantitis, various non-surgical and surgical therapies have been
advocated to eliminate the established biofilm and to resolve peri-implant infection and restore
peri-implant tissues. These therapies include mechanical debridement of the implant surface,
chemical conditioning of the implant surface, laser therapy, implantoplasty, access flap surgery
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with or without regenerative procedures, as well as topical or systemic antibiotics and/ or
antimicrobial therapy.29, 30
In 2012, a systematic review of randomized clinical trials was conducted with the aim to
evaluate the efficacy of non-surgical treatment of peri-implantitis. It showed that submucosal
debridement with adjunctive local antibiotics, glycine powder air polishing, or Er:YAG laser
treatment may reduce clinical signs of peri-implant mucosal inflammation relative to submucosal
debridement with adjunctive irrigation with chlorhexidine. However, there was still lack of result
on the efficacy of non-surgical therapy on bone loss or implant survival rates in this study.31
Another systematic review in 2013 looked at the effectiveness of reconstructive procedures
for treating peri-implantitis. Only 1 randomized controlled trial was found at that time, thus case
series studies were also included in that systematic review, with a total of 12 studies finally
included. The results showed that reconstructive therapies with the combination of implant surface
detoxification, different grafting material and membranes had a weighted mean radiographic
defect fill of 2.17mm (95% confidence internal (CI): 1.46-2.87mm), a probing depth reduction of
2.97mm (95% CI 2.38- 3.56mm), clinical attachment level gain of 1.65mm (95% CI: 1.172.13mm), and bleeding on probing reduction of 45.8% (95% CI 38.5-53.3%) for ≥ 12 months of
follow-up.32
To date, there is still no consensus on the best treatment modality for peri-implantitis. But
to cocktail different treatment methods to reduce pathogenic bacteria to greater extent should still
be the utmost consideration in order to save failing implants due to peri-implantitis.

Objectives
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Since biofilm is a recognizable etiological factor for peri-implant diseases, it is
hypothesized that local or systemic delivery of antibiotics combined with the mechanical
debridement may eliminate pathogenic bacteria to a greater extent compared to the mechanical
treatment. The evidence on the adjunct use of antibiotics on peri-implant diseases, however,
remains insufficient33, 34. Therefore, the aim of the current systematic review and meta-analyses is
to assess the clinical and microbiological effects of adjunct use of local or systemic antibiotics in
the treatment of peri-implant diseases.
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Statement of PICO Question

PICO question- Does adjunct antibiotics have additional clinical or microbiological effect on the
treatment of peri-implant diseases compared to treatment without adjunct antibiotics?

P: patients with peri-implant diseases

I: surgical or non-surgical treatment for peri-implant diseases adding adjunct antibiotics

C: surgical or non-surgical treatment for peri-implant disease without adding adjunct antibiotics

O: outcome measures regarding clinical parameters, treatment success, and microbiological shift
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Introduction

Dental implants have become a reliable alternative treatment for missing tooth in day-to-day
practice. With an increasing number of implant placements, the prevalence of peri-implant
diseases has also increased over time35, 36. At the First European Workshop on Periodontology in
1993, peri-implant diseases were defined as destructive inflammatory processes affecting the soft
and hard tissues surrounding osseointegrated dental implants in function14. There are two types of
peri-implant diseases; peri-implant mucositis: a reversible inflammatory reaction confined to soft
tissues and peri-implantitis which irreversibly extends to the supporting bone14, 15.

Extensive evidence has shown that bacteria in the subgingival plaque plays an important role in
the initiation and progression of peri-implant diseases37-41. Hence, the goal of peri-implant diseases
treatment is to decrease the total bacterial load. Various non-surgical and surgical therapies have
been advocated to approach this goal with conflicting outcomes having been reported, these
therapies include: mechanical surface debridement, laser treatment, implantoplasty, resective and
regenerative surgical procedures29,

42-45

. Since outcomes of peri-implant disease therapies are

unpredictable, it has been suggested that anti-infective measures should also be included into the
treatment17, 43, 46, 47.

Based on the understanding that biofilm is relatively resistant to antimicrobial therapy,
administration of antibiotics accompanied by disruption of plaque with mechanical debridement
is a widely accepted treatment modality24, 48, 49. Consequently, the adjunct use of antibiotics has
been extensively studied and has consistently shown to provide clinical benefits in the treatment
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of periodontitis50, 51. With the hypothesis that peri-implant pathogens might be easily retained on
the rough implant surfaces capable of invading soft tissue, this supportive treatment has also been
applied to peri-implant diseases52. However, the benefit of adjunct use of antibiotics for periimplant diseases remains controversial33, 43, 53.

The previous reviews discussing antibiotics in the treatment of peri-implant diseases highlighted
the need of more randomized controlled trials (RCTs) to strengthen the evidence33, 43. To our
knowledge, no meta-analysis has been conducted to evaluate the additional use of antibiotics in
surgical or non-surgical peri-implant treatment. Therefore, the aim of this systematic review and
meta-analysis of RCTs was to assess the clinical and microbiological effects of adjunct use of
localized or systemic antibiotics in the treatment of peri-implant diseases.

18

Material and Methods

This article adhered to the Preferred Reporting Items for Systematic Reviews and MetaAnalysis (PRISMA) guidelines54 for developing a focused question in PICO (participants,
interventions, comparison, outcomes) format, which is: “Does adjunct antibiotics (I) have any
favorable effect upon clinical parameters or microbiological shift (O) in patients with peri-implant
diseases (P), compared to any treatment without adjunct antibiotics ?” A protocol was registered
at PROSPERO (Registration No. CRD42018114147) before this systematic review and metaanalysis was started to avoid potential biases.

Search strategy
A systematic search was conducted by a librarian (L.G.) to address the PICO question
through the following databases: PubMed (Medline), Elsevier EMBASE, Web of Science, and
Cochrane Central Register of Controlled Trials (CENTRAL), EBSCO-Dentistry and Oral Science
Source, and WHO International Clinical Trials Registry Platform (WHOINT). Articles from 1980
forward until March 25, 2020 were searched. The search terms included medical subject headings
(MeSH/EMTREE) and free text/ keywords by different combinations, and the strategy was as
followed: (((((("Anti-Infective Agents"[Mesh] OR "Anti-Bacterial Agents"[Mesh] OR "AntiBacterial Agents"[Pharmacological Action] OR anti-biotic* OR antibiotic* OR "anti biotic" OR
anti-bacterial OR antibacterial))) AND (("Peri-Implantitis"[Mesh] OR peri implantitis OR periimplantitis OR "peri implantitis" OR peri-implant* OR "peri implant" OR periimplant*) OR
((("Periodontal Diseases"[Mesh] OR periodontal OR periodontitis OR bony defect OR "bone loss")
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OR ("Inflammation"[Mesh])) AND ("Dental Implants"[Mesh] OR tooth implant OR teeth
implant))))))).
Two reviewers (Y-W.C., Y.W.) conducted title, abstract, and full text screenings
independently after pre-screening calibration and standardization in selection criteria were
performed. If the study passed title and abstract screen, the full-text of the article was reviewed.
When the abstract of the articles were not available, the full-text studies were reviewed. Any
disagreement between the two reviewers was discussed and resolved by consultation with the third
author (C-Y. C.).
Authors of the included studies were contacted to clarify any questions or issues of missing
data when necessary. When there was more than one publication reporting on the same patient
groups, all the studies were reviewed and the data was examined based on the determined selection
criteria.

Study selection criteria
Studies were included when they met the following inclusion criteria: patients included in
study had peri-implant mucositis or peri-implantitis treated with any treatment with a combination
of adjunct antibiotics (ABX group), either systemic or local-delivered; the comparator was the
same treatment without adjunct antibiotics (control group); primary outcomes included were
probing depth (PD) reduction, radiographic bone level (RBL) gain, and treatment success. The
secondary outcomes were bleeding on probing (BOP) and microbiological shift before and after
the treatments.
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Additionally, studies had to meet the following criteria: (1) RCTs with at least 10 subjects
enrolled in each group, (2) follow-up period of at least three months after treatment, (3) published
in English, Chinese, or Greek. Exclusion criteria: Studies lacking a control group were excluded.

Qualify assessment of studies
The risk of bias (RoB) assessment of the studies was evaluated using the revised Cochrane
risk-of-bias tool for randomized trial (Cochrane RoB 2.0)55. The following five domains were
assessed: randomization process, deviations from the intended interventions, missing outcome data,
measurement of the outcome, and selection of the reported result. After evaluating each domain,
the overall RoB assessment of each study was ranked as followed, “Low” RoB if all domains were
low RoB; “Some concerns” when if at least one domain was judged to have some concern ; and
“High” RoB when at least one domain had high RoB or multiple domains were judged to have
some concerns that substantially lowered the confidence in results.
Two authors (Y-W.C., Y.W.) independently performed the assessment. Any discrepancy
was resolved between the two authors to reach an agreement.

Data extraction
A standardized tabulation was generated by one author (Y-W.C.) to facilitate data
extraction, in which the following items were included: study design, patient demographics, types
of peri-implant diseases, primary treatment modalities, types of adjunct antibiotics, antibiotics
delivery method, and follow up period. Variables regarding outcome measurements were
independently retrieved by two reviewers (Y-W.C., Y.W.), which included: (1) sample size of
patients and number of implants with peri-implant diseases, (2) changes on BOP, (3) changes on
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PD, (4) changes on RBL, (5) number of treatment success, and (6) microbiological examination
findings. The data for each study were entered into electronic spreadsheets.

Data synthesis and analysis
We calculated PD reduction by subtracting the PD at the follow-up measurement from the
PD before treatments were given. The weighted mean difference of PD reduction (WMDPD) were
estimated by subtracting the PD reduction in the ABX group from PD reduction in the control
group. A positive value indicated that the ABX group had more PD reduction than the control
group and vice versa. Then we pooled the differences of PD reduction between two groups in each
study on the basis of assigned weights. For the changes in radiographic bone level (RBL). We
calculated RBL gain by subtracting the bone level at the last measurement from the bone level at
baseline. We calculated the weighted mean difference of RBL gain (WMDRBG) by subtracting
the RBL gain in the ABX group from the RBL gain in the control group. Then we pooled the
differences of RBL gain between two groups in each study on the basis of the assigned weights. A
positive value of WMDRBG indicated that ABX group had more bone gain than the control group
and vice versa. Odds ratio (OR) for ABX group and control group were used to calculate overall
treatment success rate, presented by weighted pooled odds ratio (WPOR). We also looked at BOP
and microbiological findings, which were synthesized without meta-analysis.
Random effects meta-analyses of the selected studies were applied to avoid any bias caused
by methodological differences among the studies. Forest plots were generated to graphically
represent the difference in outcomes of ABX and control groups for all included studies, using the
implant as the unit of analysis. If the study included multiple groups that qualified for data analysis,
we extracted the data from each group and treated each data set independently. For the paired data
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obtained from the pre-post studies, the correlation was calculated and used for meta-analysis. An
estimated correlation value would be assumed for studies that did not report enough information
to calculate the correlation (standard deviations of the baseline, post-intervention and difference).
Heterogeneity was assessed using I2 tests, which ranged between 0% and 100%; lower values
represented less heterogeneity. To evaluate the variables causing heterogeneity or result bias, we
conducted subgroup analysis. All statistical analysis was performed (by C-Y. C.) using the Review
Manager (RevMan) software (Review Manager, version 5.3, The Nordic Cochrane Center,
Copenhagen, Denmark). A P value of .05 was used as the level of significance.

Grading of evidence
According to the Grading of Recommendations Assessment, Development, and Evaluation
(GRADE) system, the quality of evidence was assigned to each outcome across studies by the
following criteria: Study design, risk of bias, consistency, precision, publication bias and, other
considerations. Consistency was judged based on the heterogeneity (I2) of each outcome, and was
ranked as: Not serious, 0-30%; serious, 30-75%; and very serious, > 75%. Precision was judged
based on total sample size; it was ranked as not serious if total sample size was larger than 40,
serious if between 20-40, and very serious if smaller than 20. Publication bias was assessed when
outcomes had more than 10 articles included for quantitative analysis. The GRADE system results
in four grades in rating the quality of evidence: high, moderate, low and very low.
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Results
A total of 856 non-duplicated articles were found by the search strategy (Figure 1). We
identified 54 articles after reviewing the titles and abstracts. After full text review, 44 articles were
excluded due to wrong study design, wrong treatment, or incomplete data for outcome assessments.
Finally, 10 articles met the inclusion criteria and qualified for qualitative assessment and
descriptive synthesis. Among those studies, a study done by Carcuac in 201756 used the same
cohort as the 2016 study done by the same author57 but with different follow-up periods. Three
studies58-60 were not used for meta-analysis due to lack of available data and the results were
calculated by patient numbers but not implant numbers. Finally, seven articles were included for
quantitative synthesis56, 57, 61-65.
.

Figure 1. Flow chart of article screening
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Qualify assessment of studies
The risk of bias in each study was summarized according to Cochrane RoB 2.0 (Figure 2).
The randomization sequence generation process was not clearly addressed in two studies60, 62
(Schrenk 1997 & Gomi 2015). Another two studies56, 64 (Carcuac 2017 & Hallstrom 2017) had
more than 10% of participants lost follow-ups, which led to some concerns in the missing outcome
data domain. There are also some concerns on the measurement of the outcomes in three of the
studies58, 60, 62 (Schrenk 1997, Buchter 2004, Gomi 2015), because they did not mention about
blinding of examiners. Finally, there is one study60 (Schrenk 1997) having high risk of bias on the
selection of the reported result, because they made measurements on the probing depth, attachment
level, and probing bone level but did not provide the results of them.

Figure 2. Risk of bias assessment for each study
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Overall, five articles57, 59, 61, 63, 65 (Hallstrom 2012, Carcuac 2016, Chia 2019, Shibli 2019,
Deeb 2020) were ranked as low risk of bias, four articles56, 60, 62, 64 (Schrenk 1997, Gomi 2015,
Carcuac 2017, Hallstrom 2017) were ranked as some concerns, and one article60 (Schrenk 1997)
was ranked as high risk of bias.

Description of Studies
The characteristics of the ten included studies are summarized (Table 1). A total of 596
implants in 355 patients were evaluated in the selected study cohorts. The mean ages of patients
in each of the studies were from 51.5 to 69.9 years. The follow-up periods ranged from one month
to 36 months. One study58 (Buchter 2004) did not mention exclusion criteria; while all the other
studies excluded cases with history of compromised general health or antibiotics 3 or 6 months
prior to beginning of the study. Only two studies excluded smokers from their sample populations61,
62

(Cha 2019, Gomi 2015), while one study only included current smokers59 (Deeb 2020). Among

ten studies, three of them were looking at peri-implant mucositis59, 60, 63 (Schrenk 1997, Hallstrom
2012, Deeb 2020), the other seven studies were looking at peri-implantitis56-58, 61, 62, 64, 65 (Buchter
2004, Cha 2019, Gomi 2015, Carcuac 2016, Carcuac 2017, Hallstrom 2017, Shibli 2019).
The primary treatment for peri-implant mucositis59, 60, 63 (Schrenk 1997, Hallstrom 2012,
Deeb 2020) was performed by scaling/ debridement followed by rubber cup polishing, while the
primary treatment for peri-implantitis was performed by subgingival scaling/ debridement with or
without open flap technique. Three studies56-58 (Buchter 2004, Carcuac 2016 & 2017) had used
chlorhexidine irrigation for implant surface decontamination after debridement. Adjunct
antibiotics intervention was administered either locally (three studies)58,

60, 61

(Schrenk 1997,

Buchter 2004, Cha 2019) or systemically (seven studies)56, 57, 59, 62-65 (Hallstrom 2012, Gomi 2015,
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Carcuac 2016, Carcuac 2017, Hallstrom 2017, Shibli 2018, Deeb 2020). However, in Cha’s study,
they used both local and systemic antibiotics: the local minocycline ointment, Periocline, was the
intervention of interest and used in the test group only, while systemic Amoxicillin were prescribed
for both test and control groups 3 days postoperatively (Cha 2019).
Synthesis on the results of BOP
Table 2 shows the summarized treatment outcomes of included studies. All of the studies have the
results on either post-treatment BOP or mean changes of BOP by percentages. The percentage was
calculated by the number of BOP sites divided by the number of total measurement sites around
the implants. In general, all studies showed reduction of BOP percentages around the implants
after the treatments, and most of the studies revealed more reduction in ABX groups compared to
control groups.
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Table 1. The summary of characteristics of articles
Study

Study
Design

No. of
Patients
and
Implants

Peri-implant
pathology and
definition

Mean
age
(range)

Exclusion criteria

Primary treatment

Systemic/
Local
antibiotics
(drug name)
used in test
group

Delivery method

Postoperative
care

F/U
time

Splitmouth
RCT

8 patients,
24
implants

Peri-implant
mucositis (PD >=
4mm with BOP,
no peri-implant
bone loss on
radiographs)

62
(range
53-69)

Scaling, followed by
rubber cup polishing

Local
(tetracycline
HCL)

4, 12
weeks

Peri-implant
mucosal
hyperplasia

ABX delivery by
monolithic ethylene
vinyl acetate fiber,
then an isobutyl
cyanoacrylate
adhesive applied to
secure the fiber.
Total 1 time of ABX
with a duration of 10
days

0.2% CHX
rinse twice
daily

6 patients,
7 implants

(1) Systemic disorders
(2) rheumatic heart disease, congenital
heart defects, artificial heart valve or
artificial joint replacements
(3) Allergies to tetracycline or local
anesthesia
(4) Oral yeast infections
(5) Taking systemic ABX within 3
months prior to baseline exam

Local antibiotics
Schrenk G
1997

Buchter A
2004

RCT

28 patients,
48
implants

Periimplantitis
(radiographic
evidence of bony
defects >50%
length of implant)

55
(range
25-78)

NA

Scaling and
irrigation with 0.2%
CHX

Local
(doxycycline,
Atridox)

ABX delivery by
injection of ABX
solution via 23gauge blunt cannula
into the peri-implant
pocket. Total 1 time
of antibiotics

OHI

4
months

Cha JK
2019

RCT

46 patients,
46
implants

Peri-implantitis
(PD>5 mm with
BOP, and
radiographic
evidence of bone
loss>2 mm)

61.6
(range
40-84)

(1) pregnancy or lactation, (2) taking
drugs that can affect periodontal
disease (phenytoin, cyclosporin,
calcium-channel blocker), (3) taking
coumadin or NSAID, (4) diabetes
mellitus (5) smoking, (6) uncontrolled
systemic diseases, (8) allergic to TCN,
(9) use CHX or any other type of
mouth rinse (10) take ABX within the
previous 3 months

OFD

Local
(minocycline,
Periocline)

Application of local
ABX subgingivally,
repeated with
debridement at 1, 3,
6 months

Amoxicillin
500mg 3
times per
day for 3
days

1, 3, 6
months

46 patients,
46
implants

Peri-implant
mucositis (PD >=
4mm with BOP
and/ or
suppuration on
probing)

54.6 +/18.2
(test
group)

(1) If >=2.0mm bone loss from
radiographs taken at the time of
completion of the prosthetic
restoration
(2) pregnant or breast feeding
(3) diagnosis of diabetes mellitus
(4) allergic to erythromycin or other
macrolides

Scaling followed by
rubber cup polishing

Systemic
(Azithromycin)

500mg daily on
Day1 and 250mg on
Day 2-4. Total 5
days of antibiotics

OHI

1, 3, 6
months

Systemic antibiotics
Hallstrom H
2012

RCT

54.6 +/19.8
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(control
group)

Deeb MA
2020

RCT

30 patients,
30
implants

Peri-implant
mucositis (BOP,
no peri-implant
bone loss on
radiographs)

51.5 +/2.31

Gomi K
2015

RCT

Peri-implantitis
(PD>= 4mm with
BOP and
radiographic
evidence of bone
loss)

67.6
(range
55-78)

Carcuac O
2016

RCT

20 patients,
145
implants*
(count
from
average
No. of
implants
multiplied
by No. of
patients)
100
patients,
179
implants

Severe periimplantitis (PD>=
6mm with BOP
and/ or
suppuration on
probing, and
radiographic
evidence of bone
loss> 3mm)

Carcuac O
2017

RCT

100
patients,
179
implants

Severe periimplantitis (PD>=
6mm with BOP
and/ or
suppuration on
probing, and
radiographic
evidence of bone
loss> 3mm)

(5) used steroid or other antiinflammatory medication
(6) used medications known to have
effects on gingival growth
(7) history of taking systemic
antibiotics in 3 months previously
(1) Not current smoker, (2) pregnancy
or breastfeeding, (3) use steroids or
anti-inflammatory drug, (4) having
systemic conditions such as chronic
hyperglycemia, renal disorders, AIDS,
and terminal illness

Scaling followed by
rubber cup polishing

Systemic
(Azithromycin)

500mg daily on
Day1 and 250mg on
Day 2-4. Total 5
days of antibiotics

0.12%
CHX rinse
twice daily
for 14d
postoperatively

6 and
12
weeks

(1) systemic or topical antibiotics in
the preceding 3 months
(2) allergic to macrolide
(3) systemic illness
(4) current smoker or smoking 5 years
prior to the study

Scaling

Systemic
(Azithromycin)

500mg daily for 3
days before scaling.
Total 3 days of
antibiotics

OHI

1, 3, 6,
9, 12
months

66.3+/13.6

(1) compromised general health
(2) systemic antibiotic therapy during
the past 6 months
(3) allergy to PCN

Rubber cup
polishing
supragingivally,
followed by OFD,
bone recontouring,
and decontamination
with or without
0.2% CHX
digluconate solution

Systemic
(AMX)

1500mg daily
started 3 days before
surgical treatment,
kept until posttreatment 7 days.
Total 10 days of
antibiotics

OHI prior
to and after
surgery,
and 0.2%
CHX rinse
twice daily
for 14d
postoperatively

6, 12
months

66.3+/13.6

(1) compromised general health
(2) systemic antibiotic therapy during
the past 6 months
(3) allergy to PCN

Rubber cup
polishing
supragingivally,
followed by OFD,
bone recontouring,
and decontamination
with or without
0.2% CHX
digluconate solution

Systemic
(AMX)

1500mg daily
started 3 days before
surgical treatment,
kept until posttreatment 7 days.
Total 10 days of
antibiotics

OHI prior
to and after
surgery,
and 0.2%
CHX rinse
twice daily
for 14d
postoperatively

36
months
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Hallstrom H
2017

RCT

31 patients,
31
Implants

Peri-implantitis
(PD>=5mm with
BOP and/or
suppuration on
probing, and
radiographic
evidence of bone
loss>=3 mm)

69.9
(range
26-86)

(1) Diabetes mellitus
(2) history of systemic antibiotics in
the preceding 3 months
(3) anti-inflammatory medications or
medications with known gingival
effects
(4) ABX prophylaxis

OFD

Systemic
(Azithromycin)

500mg at the day of
surgery, and 250mg
daily
postoperatively for 4
days

OHI and
then 0.2%
CHX rinse
twice daily
for 10d
postoperatively

12
months

Shibli JA
2019

RCT

40 patients,
40
implants

Peri-implantitis
(PD>5mm with
BOP and/ or
suppuration on
probing, and
radiographic bone
loss >4mm,
>=50% periimplant bone
retained relative to
implant length

58.5 +/11.1

(1) Pregnancy, (2) current smoker, (3)
any systemic disease that could affect
peri-implantitis progression, (4) prior
history of non-surgical peri-implant
debridement, antibiotics or antiinflammatory therapy within the
previous 6 months, (5) allergic to
metronidazole and/ or amoxicillin

Scaling

Systemic (MTZ
and AMX)

400mg MTZ and
500mg AMX, three
times a day. Total
14 days of
antibiotics

Subgingival
maintenanc
e therapy
every 3
months

3, 6, 12
months

ABX, antibiotics; AMX, amoxicillin; BOP, bleeding on probing; CHX, chlorhexidine; F/U, follow-up; MTZ, metronidazole NA, non-applicable; OFD, open flap debridement; OHI, oral hygiene
instruction; PCN, penicillin; PD, probing depth; RCT, randomized clinical trial; TCN, tetracycline.
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Table 2. Treatment outcomes of included articles
Study/
Disease

Definition of
BOP/SOP

Mean BOP reduction
(%)

Definition of mean
PD

PD reduction
Mean +/- SD (mm)

Worst site PD
reduction
Mean +/- SD (mm)

Bone level changes
radiographically
Mean +/- SD (mm)

Microbiological
findings

Schrenk G
1997/ PIM

Percentage of BOP+
at 6 sites around
implants

12-week:
ABX 17%
Control -15%

Mean of PDs
measured at 6 sites
at each implant

Not provided

NA

NA

NA

Buchter A
2004/ PI

Percentage of BOP+
at 4 sites around
implants

4-month:
ABX 27%
Control 13%

Mean of PDs
measured at 4 sites
at each implant

4-month:
ABX 1.15 +/- 0.23
Control 0.56 +/- 0.30

NA

NA

NA

Cha JK 2019/
PI

Percentage of BOP+
at 4 sites around
implants

6-month:
ABX 49%
Control 31%

Mean of PDs
measured at 4 sites
at each implant

6-month:
ABX 2.68 +/- 1.73
Control 1.55 +/- 1.86

6-month:
ABX 3.58+/-2.32
Control 2.45+/-2.13

6-month:
ABX 0.72
Control 0.31

Number of red
complex bacteria in
both groups tended
to decrease at 6month after
treatment. But
no group differences
in changes in red
complex bacteria at
all time points

Local antibiotics

Systemic antibiotics
Hallstrom H
2012/ PIM

Percentage of BOP+
at 4 sites around
implants

1-month:
ABX 44.6%
Control 25.8%
3-month:
ABX 44%
Control 41.5%
6-month:
ABX 55.3%
Control 32.5%

Mean of PDs
measured at 4 sites
at each implant

1-month:
ABX 0.9
Control 0.6
3-month:
ABX 0.9
Control 0.7
6-month:
ABX 0.9
Control 0.9

1-month:
ABX 1.0
Control 0.9
3-month:
ABX 1.1
Control 0.8
6-month:
ABX 1.4
Control 0.8

NA

No study group
differences in
baseline bacterial
counts for all
species studied, nor
differences in the
changes of bacterial
counts between
baseline and the
F/Us

Deeb MA
2020/ PIM

Percentage of BOP+
at 4 sites around
implants

Baseline:
ABX 15.7 +/- 3.9
Control 13.6 +/- 4.0
6-week:
ABX 12.6 +/- 3.8
Control 12.0 +/- 4.1
3-month:
ABX 10.1 +/- 3.1
Control 11.8 +/- 4.0

Mean of PDs
measured at 4 sites
at each implant

6-week:
ABX 0.6 +/- 1.05
Control 0.2 +/- 0.85
3-month:
ABX 0.75 +/- 1.05
Control 0.4 +/- 0.92

NA

NA

Only the ABX
group had
statistically
significant reduction
of Pseudomonas
aeruginosa and
Staphylococcus
aureus from baseline
to 12 weeks.
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Gomi K
2015/ PI

Percentage of BOP+
at 6 sites around
implants

1-month:
ABX 25.2%
Control 8.4%
3-month:
ABX 25.3%
Control 5.9%
6-month:
ABX 24.5%
Control 6.1%
9-month:
ABX 23.7%
Control 5.3%
12-month:
ABX 23.5%
Control 5.9%

Mean of PDs
measured at 6 sites
at each implant

1-month:
ABX 0.84
Control 0.23
3-month:
ABX 0.93
Control 0.27
6-month:
ABX 0.91
Control 0.23
9-month:
ABX 0.94
Control 0.25
12-month:
ABX 0.94
Control 0.13

NA

NA

Porphyromonas
gingivalis,
Treponema
denticola, Prevotella
intermedia were
more effectively
reduced in the test
group than the
control group, but
they gradually
increased around
implants 6 months
after treatment.

Carcuac O
2016/ PI

Percentage of BOP+
at 4 sites around
implants

No baseline data
No BOP change data

Mean of PDs
measured at 4 sites
at each implant

6-month:
ABX and CHX 3.03 +/-1.58
ABX only 3.49 +/- 1.54
CHX only 2.18 +/- 1.54
Control 1.95 +/- 1.81
12-month:
ABX and CHX 2.80 +/- 1.87
ABX only 3.44 +/- 1.66
CHX only 2.16 +/- 1.79
Control 1.69 +/- 2.22

NA

12-month:
ABX+CHX 0.18+/-1.15
ABX only 0.51 +/- 0.84
CHX only -0.69 +/- 1.32
Control -0.96 +/- 1.42

NA

Carcuac O
2017/ PI

Percentage of BOP+
at 4 sites around
implants

No baseline data
No BOP change data

Mean of PDs
measured at 4 sites
at each implant

36-month:
ABX -3.00 +/- 2.24
Control -2.38 +/- 2.55

NA

36-month:
ABX 0.32 +/- 1.35
Control -0.51 +/- 1.87

NA

Hallstrom H
2017/ PI

Percentage of BOP+
at 4 sites around
implants

12-month:
ABX 87.6%%
Control 86.7%

Mean of PDs
measured at 4 sites
at each implant

6-month:
ABX 1.5
Control 1.3
12-month:
ABX 1.7
Control 1.6

NA

12-month:
ABX 0.6
Control 0.4

At 12-month, 25.8%
individuals
presented with no
detectable level of
nine bacterial
species associated
with periimplantitis.
But no group
differences in
changes in bacterial
load overtime
compared to the
baseline values
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Shibli JA
2019

Percentage of BOP+
at 6 sites around
implants

Baseline:
ABX 86.6 +/- 32.2
Control 85 +/- 18.3
3-month:
ABX 74.9 +/- 36.2
Control 74.9 +/- 30.6
6-month:
ABX 40.4 +/- 34.5
Control 36.6 +/- 25.8
12-month:
ABX 35.6 +/- 26.2
Control 36.6 +/- 25.8

Mean of PDs
measured at 6 sites
at each implant

3-month:
ABX 1.4
Control 0.4
6-month:
ABX 3.1
Control 2.1
12-month:
ABX 3.1 +/- 1.2
Control: 1.8 +/- 0.2

3-month:
ABX 3.0
Control 0.9
6-month:
ABX 4.7
Control 3.3
12-month:
ABX 4.8
Control 3.8

12-month:
ABX 0.41 +/- 0.39
Control 0.47 +/- 0.31

ABX, antibiotics group; BOP, bleeding on probing; F/U, follow-up; NA, non-available; PD, probing depth; PI, peri-implantitis; PIM, peri-implant mucositis
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Number of red
complex bacteria in
both groups had
significant reduction
at 14 days and 3month after
treatment. But more
reduction in the
ABX group than
control group
compared to
baseline at 1-year

Synthesis on the results of PD
PD have been assessed in all of the ten studies, but only nine studies reported the outcomes
of PD, and six of them calculate the mean PD by implant numbers. Therefore, meta-analysis was
conducted for those six studies to estimate the WMDPD between ABX and control treatments.
For the 3-month (short-term) effect, all three included studies used systemic antitbioics as
adjunct treatments62,

63, 65

(Hallstrom 2012, Shibli 2019, Gomi 2015). In general, systemic

antibiotics had beneficial effect on more PD reduction (WMDPD, 0.56; 95% CI, 0.22-0.90, p=
0.001). But subgroup analysis revealed this beneficial effect was significant only in periimplantitis but not in peri-implant mucositis (Figure 3) The quality of evidence was moderate
(supplementary table 1).

Figure 3. Short-term (3 months) changes on probing depth (all systemic antibiotics)

For the 6-month effect, meta-analysis of six studies57, 61-65 (Cha 2019, Carcuac 2016, Gomi
2015, Hallstrom 2012, 2017, Shibli 2019) showed the ABX groups had significantly more PD
reduction compared to control groups (WMDPD, 0.82; 95% CI, 0.50-1.14, p<0.00001), especially
for peri-implantitis (WMDPD, 0.83; 95% CI, 0.52-1.13, p<0.0001) (Figure 4a). The quality of
34

evidence was low due to high heterogeneity of studies (supplementary table 1). Subgroup analysis
according to whether local or systemic antibiotics was used showed both types of antibiotics had
beneficial effect on reducing more probing depth (Figure 4b). For the 12-month effect, all of the
four studies57,

62, 64, 65

(Carcuac 2016, Gomi 2015, Hallstrom 2017, Shibli 2019) were peri-

implantitis cases using systemic antibiotics as adjunct treatment. The meta-analysis also showed a
better result from ABX groups in PD reduction compared to control groups (WMDPD, 0.92; 95%
CI, 0.51-1.32, p< 0.0001) (Figure 5). The quality of evidence was low due to high heterogeneity
(supplementary table 1)

Figure 4 (a). Six months changes on probing depth, subgroup by disease
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Figure 4 (b). Six months changes on probing depth, subgroup by antibiotics

Figure 5. Long-term (12 months) changes on probing depth (all systemic antibiotics and periimplantitis)
Radiographic bone level
Four studies were included57, 61, 64, 65 (Cha 2019, Carcuac 2016, Hallstrom 2017, Shibli
2019); three studies57, 64, 65 (Carcuac 2016, Hallstrom 2017, Shibli 2019) had 12-month outcomes
and one study (Cha 2019) had a 6-month outcome. The meta-analysis showed more gain of bone
in favor of using adjunct ABX (WMDRBG, 0.64; 95% CI, 0.05-1.23, p= 0.03) (Figure 6). The
quality of evidence was very low due to inconsistency and high heterogeneity (supplementary
table 1).
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Figure 6. Outcome of radiographic bone gain (6 to 12 months) (all peri-implantitis)

Supplementary Table 1

Treatment success

37

Four studies56, 61, 64, 65 (Cha 2019, Carcuac 2017, Hallstrom 2017, Shibli 2019) provided
comparison of treatment success of peri-implantitis between ABX and control groups. Their
definition of treatment success is similar, and all included PD equal and/ or less than 5mm, no
bleeding or suppuration on probing, and no or less than 0.5 mm further bone loss at 6 months or
12 months after the treatment. Therefore, meta-analysis can be conducted. It showed the ABX
group presented a significantly greater treatment success when compared to the control group
(WPOR, 1.74; 95% CI, 1.03- 2.94, p=0.04) (Figure 7). The quality of evidence was moderate
(supplementary table 2).

Figure 7. Meta-analysis on treatment success (6 to 12 months) (all peri-implantitis)
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Supplementary Table 2
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Discussion
Summary of the main finding
In the present study, we found that adjunct use of antibiotics provides significant clinical
benefits in the treatment of peri-implant diseases, including PD reduction, radiographic bone gain
and treatment success in the meta-analysis. This additional clinical benefit with antibiotics is
especially significant when applied to peri-implantitis cases but not as much to peri-implant
mucositis cases based on the subgroup analysis.
Similar to the progression from gingivitis to periodontitis, peri-implant mucositis is the
precursor of peri-implantitis66, and it is usually considered to be an inflammatory lesion confined
to the soft tissue surrounding implants without the loss or continuing loss of supporting bone67;
whereas peri-implantitis is characterized by the inflammation found in the peri-implant soft tissue
that leads to progressive loss of supporting bone68. Yet, it is challenging to define a clear cut
between these two diseases clinically due to the difficulty of detecting the initiation of the
pathological bone loss. Therefore, the case definitions of peri-implant mucositis and periimplantitis varies in between studies69-71 and is the reason we included both diseases in our study
to provide a more comprehensive assessment.

Local and systemic antibiotics
Local controlled delivery of antibiotics has been used to treat peri-implant diseases in order
to maintain the high concentrations in the defect60, 72, 73. Three studies evaluating the effect of
different type of local antibiotics58, 60, 61 were included in our review, but two were excluded from
the meta-analysis due to the lack of quantitative data60 or missing information of the implant

40

numbers58. Thus, our meta-analysis cannot draw firm conclusion for local antibiotics in the
treatment of peri-implant diseases since only one study61 fits our stringent criteria to evaluate the
true adjunct effect of antibiotic for quantitative analysis. Although these three RCTs cannot be
analyzed together, we can still see a trend from the original studies that local antibiotics appeared
to be effective in the treatment of peri-implantitis, but not as much in peri-implant mucositis. This
finding is also in line with other systematic review and controlled trials33, 74-77.
Pertaining to the use of adjunct systemic antibiotics in the treatment of peri-implant
diseases, the subgroup analysis provides a mean difference from 0.56 to 0.92 mm in PD reduction,
favoring ABX group at all follow up time points (Figure 3, 4b, 5), but the benefit in radiographic
bone gain (Figure 6) and treatment success (Figure 7) is not significant. Specifically, for periimplantitis, the current meta-analysis proved that significant more PD reduction at 1 year can be
achieved when systemic antibiotics were applied (Figure 5). It is noteworthy that Carcuac study
highlights that the clinical benefits of systemic antibiotic were only limited to implants with
modified surfaces and the benefits fail to sustain long-term56. This could be related to the fact
modified rough implant surface harbors biofilm and bacteria reside in areas possibly sheltered
from mechanical debridement, therefore, systemic antibiotics could have a role in this scenario.
There is only one study about treating peri-implant mucositis with systemic antibiotics63 in our
analysis, thus solid conclusion cannot be drawn for this perspective.
Collectively, adjunct antibiotics showed convincing results in PD reduction, radiographic
bone gain and treatment success in the present meta-analysis. Nonetheless, we found that Cha
study61, the only included localized antibiotic study, had significant impact on the overall result.
Without Cha study, the analysis of systemic antibiotics alone failed to define significant clinical
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benefits on radiographic bone gain and treatment success (Figure 6 & 7). It should be noted that
although the focus of Cha study is the effect of repeated use of local minocycline ointment, they
also applied systemic antibiotic to both treatment groups. As a consequence, we could not
determine if the superior outcome was from the combined antibiotic therapy or the true effect of
the local antibiotic. Based on this review’s analysis, it appears that adjunct antibiotics are
potentially clinically beneficial for the treatment of peri-implant diseases, yet the most efficient
kind of antibiotic and type of delivery system remains unclear.

Microbiology
Since peri-implant diseases are bacteria induced diseases, the microbiological result can be
a good treatment outcome indicator. From culture-based techniques20,
independent investigations81,

82

76, 78-80

to cultivation-

, peri-implant diseases have been shown to be consisted of

predominantly Gram-negative anaerobic microflora, which is similar to, but less complex than
chronic periodontitis. Predominant microbiota in peri-implant mucositis is similar to periimplantitis and has been confirmed by a study using the checkerboard DNA–DNA hybridization
technique83.
The only local antibiotic study with microbiological data in this review revealed no
significant intergroup differences in the reduction of red complex bacteria at all time points61. The
post-op systemic antibiotic applied to both ABX and control groups may have potentially masked
the contribution made by local minocycline. Two studies using 5-day-course systemic
azithromycin combined with non-surgical therapy to treat peri-implant mucositis presented
inconsistent microbiological results 59, 63. One study failed to detect any advantages from the use
of antibiotics63. In contrast, the other study showed significant reduction of Pseudomonas
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aeruginosa and Staphylococcus aureus, two bacteria closely linked to implant failure84, only in
the ABX group at one year follow up59 (Deeb et al., 2020). The variance in results between these
two studies could be caused by the difference in patient populations studied. Deeb’s study only
included smokers, and smoking has been proven to influence the composition of subgingival
microbiota85. With regard to the use of systemic antibiotics for the treatment of peri-implantitis,
two studies using systemic azithromycin had different findings62, 64. Gomi et al. found that common
periodontal pathogens were more effectively reduced in the ABX group, especially
Porphyromonas gingivalis, Treponema denticola, and Prevotella intermedia, but the pathogen
gradually increased at 6 months. In the other study, the statistical analysis of checkerboard DNADNA hybridization failed to identify different total bacterial load between groups at any time point
without showing the information of individual bacteria64. Shibli et al. echoed Gomi’s finding with
a combination of systemic antibiotics (metronidazole + amoxicillin); in the study, red complex
species are still in significantly lower proportions at 12 months compared to baseline in the ABX
group, but control group showed no difference from baseline65.
The inconsistent microbiological results among studies could be due to differences in
microbial analysis methods and the varied ways biofilm is collected. Although most of the included
studies collected subgingival biofilm from the deepest pocket around implant with paper points,
there is one study that used gracey curette instead65. The microbiological analysis also varied in
between studies, from PCR, real-time PCR to checkerboard DNA-DNA hybridization. All the
microbiological methods in the selected studies were “close-ended” techniques, with limited
numbers of targeted taxa detected. In the future, the “open-ended” sequencing-based techniques
might be applied for microbiological evaluation to provide an unbiased assessment of the whole
bacterial profile in peri-implant lesions.
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Strength and Limitation
To our knowledge, all available literature does not report quantitative data on the use of
adjunct antibiotics for peri-implant diseases. Our current systematic review and meta-analysis
aimed to evaluate the overall antimicrobial effect of local or systemic antibiotics on peri-implant
diseases, and we were able to quantify the clinical outcome using subgroup analysis and sensitivity
test.
The results should be interpreted with caution due to the limitations in the current review:
1. Due to the lack of an established standard antibiotics regimen for peri-implant mucositis and
peri-implantitis and well-executed RCTs, the quality of evidence for the outcome was downgraded
mostly due to high heterogeneity and risk of bias. 2. BOP was presented differently among studies
which cause difficulty in performing meta-analysis, thus, this current review failed to quantify the
effect of antibiotics on BOP reduction. Consequently, in order to draw a more precise conclusion
for this topic, more well-designed RCTs for both local and systemic antibiotics in the adjunct use
of peri-implant treatments should be conducted in the future.

Conclusion
The results of this meta-analysis support that the use of adjunct antibiotics provides
additional benefit in the treatment of peri-implant diseases in all clinical assessments we analyzed,
and this effect is especially significant in peri-implantitis cases. The most consistent advantage is
the PD reduction, with almost 1mm more improvement favoring adjunct antibiotic group at one
year follow up.
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